Related news from
Thu, 25 Apr 2024 14:02:05 +0000	Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu, 25 Apr 2024 13:55:05 +0000	Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock Multiple insiders secured a larger position in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares over the last 12...
Wed, 24 Apr 2024 12:30:00 +0000	Sarepta Therapeutics to Announce First Quarter 2024 Financial Results CAMBRIDGE, Mass., April 24, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.
Sun, 14 Apr 2024 01:39:18 +0000	10 Unstoppable Stocks That Will Make You Richer In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out with stocks tumbling as the S&P 500 recorded its worst day since […]
Mon, 08 Apr 2024 20:13:56 +0000	Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.
Sat, 06 Apr 2024 12:45:00 +0000	2 Biotech Stocks to Buy Hand Over Fist in April These drugmakers have made important moves over the past year.
Tue, 02 Apr 2024 11:04:00 +0000	Outperforming ETF manager names a potential ‘50-bagger’ in the stock market Michael Taylor runs the Simplify Health Care ETF, which donates its management fees to Susan G. Komen for the Cure to fund breast-cancer research and help people with the disease.
Fri, 29 Mar 2024 20:00:00 +0000	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Fri, 29 Mar 2024 15:30:30 +0000	Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue? Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 29 Mar 2024 13:12:35 +0000	Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock increases 3.6% this past week One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
Mon, 25 Mar 2024 14:00:01 +0000	A Comprehensive Look at Sarepta's Growth and Innovation One of the leaders in the global DMD drugs market is expected to outperform
Sun, 17 Mar 2024 12:50:16 +0000	30 Biggest Biotechnology Companies in the World In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Thu, 14 Mar 2024 19:53:36 +0000	Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks In this article, we will take a detailed look at Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ken Fisher and Corporate Insiders Are Buying These 5 Stocks. Stocks wobbled on Thursday after a hotter-than-expected PPI report confirmed fears that inflation […]
Wed, 13 Mar 2024 12:00:00 +0000	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? The threat is still emerging, but it could be significant.
Tue, 12 Mar 2024 05:18:55 +0000	Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT) Wigzell Hans Lennart Rudolf, Director of Sarepta Therapeutics Inc (NASDAQ:SRPT), has sold 15,000 shares of the company on March 8, 2024, according to a recent SEC filing.
Mon, 11 Mar 2024 13:03:24 +0000	Billionaire Ray Dalio and Insiders Love These 10 Stocks In this article, we will take a detailed look at Billionaire Ray Dalio and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ray Dalio and Insiders Love These 5 Stocks. Investors are on tenterhooks before the latest inflation report scheduled to be out on Tuesday. While many believe a more-than-expected […]
Thu, 07 Mar 2024 04:54:58 +0000	Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT) Director Stephen Mayo has sold 3,135 shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), according to a recent SEC Filing.
Mon, 04 Mar 2024 14:47:00 +0000	Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst The upcoming regulatory decision on its latest drug could be big.
Mon, 04 Mar 2024 13:30:00 +0000	Sarepta Therapeutics to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., March 04, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:
Sat, 02 Mar 2024 12:17:28 +0000	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Shareholders might have noticed that Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) filed its annual result this time last...